Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Director departure
Quarterly results
Acq. announced
Appointed director
TherapeuticsMD, Inc. (TXMD) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/18/2023 8-K Quarterly results
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "FORM 8-K",
"TherapeuticsMD Announces Second Quarter 2023 Financial Results"
07/10/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Letter of Grant Thornton LLP"
07/06/2023 8-K Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial ...
Docs: "Fourth Amendment to Bylaws of the Company"
06/30/2023 SC 13D/A Rubric Capital Management LP reports a 19.6% stake in TherapeuticsMD, Inc.
05/17/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/17/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/05/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/01/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
05/01/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/21/2023 8-K Quarterly results
03/31/2023 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
02/27/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Amendment, to the Employment Agreement, as extended effective October 15, 2021, by and between TherapeuticsMD, Inc. and Marlan Walker",
"General Consulting and Services Agreement by and between TherapeuticsMD, Inc. and MCD Consulting Management Services, LLC"
02/13/2023 5 Form 5 - Annual statement of changes in beneficial ownership of securities:
01/18/2023 8-K Quarterly results
01/12/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
01/06/2023 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Pro Forma Financial Statements with Respect to the Transformation of the Company"
01/03/2023 8-K Resignation/termination of a director
Docs: "TherapeuticsMD Completes Transaction to License its Products to Mayne Pharma"
12/05/2022 8-K Quarterly results
12/01/2022 8-K Quarterly results
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 D Form D - Notice of Exempt Offering of Securities:
11/14/2022 8-K Quarterly results
10/31/2022 8-K Quarterly results
10/17/2022 D Form D - Notice of Exempt Offering of Securities:
10/03/2022 8-K Quarterly results
09/12/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers"
08/30/2022 SC 13D/A Rubric Capital Management LP reports a 18.3% stake in TherapeuticsMD, Inc.
08/29/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/15/2022 D Form D - Notice of Exempt Offering of Securities:
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/15/2022 8-K Quarterly results
08/08/2022 SC 13D Rubric Capital Management LP reports a 18.3% stake in TherapeuticsMD, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy